Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
7 Biotech Stocks to Buy for 100% Returns
01:19pm, Sunday, 09'th Apr 2023
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.
7 Biotech Stocks That Could Be the Next Big Thing
11:44am, Wednesday, 15'th Mar 2023
While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c
Agios to Participate in March Investor Conferences
08:26am, Thursday, 02'nd Mar 2023
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced th
Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss
01:33pm, Friday, 24'th Feb 2023
Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same.
Agios Pharmaceuticals (AGIO) Moves to Strong Buy: Rationale Behind the Upgrade
01:33pm, Friday, 24'th Feb 2023
Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript
11:35am, Thursday, 23'rd Feb 2023
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Jessi Rennekamp - Senior Director, Corporate Communications Brian Goff - C
Is Agios Pharmaceuticals (AGIO) Stock Outpacing Its Medical Peers This Year?
11:20am, Thursday, 09'th Feb 2023
Here is how Agios Pharmaceuticals (AGIO) and Alaunos (TCRT) have performed compared to their sector so far this year.
Agios to Webcast Conference Call of Fourth Quarter and Year End 2022 Financial Results on Feb. 23, 2023
07:00am, Thursday, 02'nd Feb 2023
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the
3 Under-the-Radar Biotech Stocks to Buy in 2022
10:07am, Saturday, 24'th Dec 2022
The attraction of all three biotech stocks is their potential.
Agios to Present at 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
08:00am, Wednesday, 21'st Dec 2022
CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha
Agios to Participate in December Investor Conference
08:00am, Wednesday, 30'th Nov 2022
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
03:13pm, Thursday, 17'th Nov 2022 Benzinga
Upgrades
Wolfe Research upgraded the previous rating for Matson Inc (NYSE:MATX) from Underperform to Peer Perform. In the third quarter, Matson showed an EPS of $6.89, compared to $6.53 from the year-
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
11:20am, Tuesday, 15'th Nov 2022 Zacks Investment Research
Sector ETF report for FBT
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients
09:01pm, Thursday, 10'th Nov 2022 GlobeNewswire Inc.
First and Only Disease-modifying Therapy for EU Patients with Rare Blood Disorder First and Only Disease-modifying Therapy for EU Patients with Rare Blood Disorder
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
11:20am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Smart Beta ETF report for FBT
